Search

Your search keyword '"Singh-Jasuja, Harpreet"' showing total 145 results

Search Constraints

Start Over You searched for: Author "Singh-Jasuja, Harpreet" Remove constraint Author: "Singh-Jasuja, Harpreet"
145 results on '"Singh-Jasuja, Harpreet"'

Search Results

1. Actively personalized vaccination trial for newly diagnosed glioblastoma

2. Defining the Critical Hurdles in Cancer Immunotherapy

4. Additional Tables and Figures from A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma

6. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

9. RNA editing derived epitopes function as cancer antigens to elicit immune responses

10. The European Regulatory Environment of RNA-Based Vaccines

11. Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma

13. Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma

17. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

22. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy

23. Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases

24. Effective Targeting of PRAME-Positive Tumors with Bispecific T Cell-Engaging Receptor (TCER®) Molecules

27. Cancer classification using the Immunoscore: a worldwide task force

29. Corrigendum to “New vaccination strategies in liver cancer” [Cytokine Growth Factor Rev. 36 (2017) 125–129]

30. Actively personalized vaccination trial for newly diagnosed glioblastoma

31. ATIM-20. GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

33. MP16-11 JAPANESE PHASE I/II STUDY OF MULTIPEPTIDE-BASED CANCER VACCINE IMA901 AFTER SINGLE-DOSE CYCLOPHOSPHAMIDE IN JAPANESE PATIENTS WITH ADVANCED RENAL CELL CANCER

34. A Cancer Research UK first time in human phase I trial of IMA950 (novel multi peptide therapeutic vaccine) in patients with newly diagnosed glioblastoma

35. Abstract 2789: Development of highly potent T-cell receptor bispecifics with picomolar activity against tumor-specific HLA ligands

36. Abstract 662: IMA_Detect: Mass spectrometry guided development and clinical application of a companion diagnostic for adoptive cellular therapy against tumor associated HLA peptides

37. A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma

38. Corrigendum to “New vaccination strategies in liver cancer” [Cytokine Growth Factor Rev. 36 (2017) 125–129]

39. Abstract 2291: On- and off target toxicity profiling for adoptive cell therapy by mass spectrometry-based immunopeptidome analysis of primary human normal tissues

40. Abstract 2354: Cancer vaccine development for hepatocellular carcinoma - HEPAVAC

41. Abstract 2654: GAPVAC-101 phase I trial: First data of an innovative actively personalized peptide vaccination trial in patients with newly diagnosed glioblastoma

42. Abstract A115: Cancer vaccine development for hepatocellular carcinoma – HEPAVAC

43. The regulatory landscape for actively personalized cancer immunotherapies

46. Abstract SY27-03: Biomarker-guided development of novel multi-peptide cancer vaccines - from discovery to phase lll trials.

49. Multiple synergizing factors contribute to the strength of the CD8+ T cell response against listeriolysin O

Catalog

Books, media, physical & digital resources